Group 1 - The core point of the article is the B-round financing of Nanjing Mainoway Pharmaceutical Technology Co., Ltd., which raised a significant amount in RMB, with IDG Capital and Yuanhe Origin participating as investors [1][2]. - The financing round took place on August 24, 2025, and the total amount raised is described as "hundreds of millions" in RMB [2]. - Mainoway Pharmaceutical was established in February 2021 and has a core team with over 10 years of experience in new drug research and development, having led multiple new drug projects [2]. Group 2 - The company focuses on innovative drug development by combining molecular structure innovation with new drug delivery systems, creating a platform for drug discovery and industrialization based on natural small molecules [2]. - Mainoway's product pipeline primarily targets two areas: mental disorders and disfigurement diseases, which are chosen based on the company's understanding of the current market and the broad patient base and market potential for these conditions [2].